Statera Biopharma Submits Phase I Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

By
Justin.choi
-
0
7
Statera Biopharma, Inc. announced submission to the FDA of its pilot study protocol for STAT-205 treatment of post-acute COVID-19.
[Statera Biopharma, Inc.]

Sorry, but the selected Zotpress account can't be found.

Press Release